Trial Profile

Phase 2b Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of Zagociguat in Participants With MELAS (PRIZM)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zagociguat (Primary)
Indications Lactic acidosis; Mitochondrial encephalomyopathies; Stroke
Focus Adverse reactions; Therapeutic Use
Acronyms PRIZM
Sponsors Tisento Therapeutics

Most Recent Events

08 Jan 2026 According to a Tisento Therapeutics media release, company expects to report top-line data from the study in the fourth quarter of 2026.
08 Jan 2026 Status changed from recruiting to active, no longer recruiting.
03 Nov 2025 According to a Tisento Therapeutics media release, the findings from the interview study were published on October 27, 2025, in the Journal of Patient-Reported Outcomes.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com